Dear Investor Friends:

Please join us for this virtual investor-only meeting on Friday, December 19, featuring Intrommune, a consumer health company with a revolutionary approach to peanut allergy prevention.

Intrommune’s patented platform delivers allergens via a familiar routine: brushing your teeth. This toothpaste trains the immune system and helps prevent life-threatening nut allergies.

The Investment Opportunity:

• Amount: $4 million, first closing in December/January
• Minimum investment: $100,000
• Early investors receive preferential terms
• NASDAQ IPO targeted within 36 months

Key Investment Considerations:

Validated Science, Consumer Simplicity – In the Phase 1 study for peanut allergy, patients achieved 97% adherence with 0 dropouts and 0 cases of anaphylaxis

TRACTION – Company is already generating revenue through its distribution channels in November, 2025.

Enormous Market Need with 1st Mover Advantage – Over 33 million Americans suffer from food allergies, with limited treatment options. Intrommune is the only biotech-grade product in a consumer-ready delivery formar.

Attractive Investment Terms – Attractive valuation and terms with incentives.

World Class Leadership – Company is led by some of the top names in the industry

Event Details:

Location: Online via Zoom

Date: Friday, December 19 | 11:30am EST

Please note that this meeting is for DIRECT and ACTIVE investors only. All RSVPs must be pre-registered on this Eventbrite site with the investor criteria filled out. All RSVPs are subject to review and approval.

Don’t miss out – RSVP now.

You can request investment materials by contacting Skylar Rallison at srallison@opus8.com

We look forward to hosting you and exploring this rare convergence of biotech innovation and consumer-scale opportunity.

All the best,

Tien Wong

CEO

Opus8, Inc.